Tributyrin: A Comprehensive Reference Article
1. Identity and Chemical Characterization
Chemical Names and Structure
Tributyrin, or glyceryl tributyrate, is a triglyceride in which three butyric acid molecules are esterified to a glycerol backbone. It is also known by numerous synonyms catalogued in authoritative chemical databases. These names include butanoic acid, 1,2,3-propanetriyl ester; butyrin, tri-; butyryl triglyceride; glycerin tributyrate; glycerol tributanoate; glycerol tributyrate; glyceryl tributyrate; tri-n-butyrin; tributin; tributyroin; tributyryl glyceride; and NSC 661583. Its CAS Registry Number is 60-01-5. It has a molecular weight of 302 g·mol⁻¹ and a boiling point at 310 °C. It is present in butter and can be described as a liquid fat with an acrid taste.
Natural Occurrence and Dietary Sources
Tributyrin is naturally present in certain foods, particularly dairy fats and fermented products where microbial activity promotes its formation. Butter is one of the richest dietary sources, containing short-chain fatty acid esters, including tributyrin. Full-fat dairy products such as cream and cheese also contain smaller amounts, with concentrations influenced by processing methods and the diet of dairy-producing animals. Butter contains 3–4% butyric acid in the form of tributyrin (butyryl triglyceride), making it the richest dietary source of butyrate. Grass-fed dairy has been found to contain higher butyric acid ester levels than conventionally produced alternatives. Fermented foods also contribute to tributyrin intake. Aged cheeses like Parmesan and Gouda undergo microbial-driven lipid transformations that can result in tributyrin formation.
The 1.5 g/day total dose used in the University of Michigan Parkinson's clinical trial is equivalent to the amount of tributyrin naturally present in approximately two tablespoons of butter.
Synthesis and Preparation
Tributyrin is synthesized through esterification of glycerol and butyric acid, occurring naturally in biological systems or via chemical or enzymatic methods. Enzymatic synthesis, catalyzed by lipases, is favored in industrial and pharmaceutical applications for its efficiency and specificity, and typically occurs in solvent-free systems or in organic solvents like hexane to facilitate water removal. Industrial production often relies on chemical esterification using acid or base catalysts; sulfuric acid and p-toluenesulfonic acid serve as common acid catalysts, while alkaline conditions use sodium methoxide or potassium hydroxide.
Common Forms and Preparations as a Supplement
Tributyrin is available commercially as a dietary supplement in several forms. Tributyrin has been determined to be Generally Recognized as Safe (GRAS) for use as a food ingredient in the US by the FDA, and is available over-the-counter as a supplement. It is sold in oral capsule form under brand names such as CoreBiome® and ButyraGen®. A pilot study in healthy humans reported that oral supplementation with a tributyrin complex for 21 days resulted in reduced levels of high-sensitivity C-reactive protein, suggesting a possible anti-inflammatory effect. Considering the evidence of beneficial effects following tributyrin supplementation along with the improved stability in the digestive tract compared to butyrate, tributyrin may be a more effective alternative to butyrate supplementation. Beyond capsules, tributyrin emulsions have also been developed for research settings. Its structure makes it a stable and efficient butyrate carrier.
Regulatory and Food Industry Status
Among other things, tributyrin is used as an ingredient in making margarine. In the food industry, tributyrin can be used as a flavoring agent due to its butyric acid content, which contributes to the characteristic flavor of butter and other dairy products. Tributyrin is also used in microbiological laboratories to identify the bacterium Moraxella catarrhalis. As a supplement, it falls under DSHEA dietary supplement rules in the United States, and neither tributyrin nor sodium butyrate is FDA-approved for any clinical indication.
2. Traditional and Historical Use
Tributyrin does not carry a formal record of use as an isolated compound in traditional medicine systems; it was not identified as a discrete chemical entity until the era of modern organic chemistry. However, its primary natural vehicle — butter — has a well-documented history in food and healing traditions across multiple cultures.
The term butyrate itself originates from the Greek word for butter. Butter was consumed and used medicinally in ancient Indian Ayurvedic practice (as ghee, a clarified butter) and in European and Middle Eastern traditions as both a food and a topical emollient, though these uses are attributed to butter as a whole food rather than to tributyrin as an isolated constituent. The awareness of tributyrin as a specific triglyceride within butter, and its biochemical significance, belongs entirely to modern scientific investigation rather than to any historical herbal or dietary tradition.
As an isolated supplement or prodrug compound, tributyrin has no documented traditional use. Its development as a supplement and investigational pharmaceutical has occurred within the context of twentieth- and twenty-first-century biomedical research.
3. Key Constituents and Active Compounds
Relationship to Butyrate
Tributyrin is a prodrug of natural butyrate. It is a neutral short-chain fatty acid triglyceride that is likely to overcome the pharmacokinetic drawbacks of natural butyrate as a drug. Tributyrin is a readily available trimer of butyric acid and is cleaved intracellularly by lipases into three molecules of butyric acid. In humans, tributyrin, which is naturally present in butter, is metabolized by triacylglycerol lipase into dibutyrin and butyrate.
Mechanisms of Action
The pharmacological activity of tributyrin is primarily mediated through the butyrate it releases upon hydrolysis. The following mechanisms are established in the peer-reviewed literature:
- Histone Deacetylase (HDAC) Inhibition: Butyrate acts through its histone-modifying enzyme targets, specifically the class I histone deacetylases, and through G-protein coupled receptor targets including FFAR2 and FFAR3. Studies have shown that butyrate has a protective role by acting as an HDAC inhibitor and affecting epigenetic regulation of gene expression. Tributyrin is a butyrate prodrug that after oral administration is hydrolyzed to butyrate and is able to increase plasma butyrate levels, providing HDAC inhibitory capabilities, and has better pharmacokinetic properties with low toxicity than butyrate.
- Colonocyte Energy Supply: Butyrate plays many well-documented roles in the intestine including serving as the primary fuel source for the colonocyte, regulating water and electrolyte absorption and gene expression, providing support of the epithelial barrier, modulating visceral sensitivity and intestinal motility, and ameliorating mucosal inflammation and oxidative stress.
- Anti-Inflammatory Signaling: Butyrate has many biological mechanisms of action including anti-inflammatory and immunoprotective effects, and its depletion is associated with intestinal injury.
- Intestinal Barrier Reinforcement: Chronic-binge ethanol feeding impaired intestinal tight junction (TJ) protein co-localization staining; however, tributyrin co-treatment mitigated these effects. The preservation of tight junction proteins, including claudin-1, occludin, and zonula occludens-1, is a consistent finding across multiple animal studies.
- Prodrug Pharmacokinetics: Because tributyrin is rapidly absorbed and chemically stable in plasma, it diffuses through biological membranes and is metabolized by intracellular lipases, releasing therapeutically effective butyrate over time directly into the cell. Tributyrin is a butyrate precursor that resists gastric acids to allow more butyrate to reach the colon. Once in the intestine, pancreatic lipases break the bond between the three molecules of butyrate and one molecule of glycerol, allowing a more effective delivery of butyrate within the gastrointestinal environment.
- Antiproliferative and Apoptotic Effects in Cancer Cells: Tributyrin has potent antiproliferative, proapoptotic, and differentiation-inducing effects in neoplastic cells. Tributyrin may, at least in part, exert its growth-reducing and differentiation-inducing effect in Caco-2 cells by an upregulation of the vitamin D receptor, which may provide a useful therapeutic approach in chemoprevention and treatment of colorectal cancer.
4. Scientific Evidence by Area of Use
4.1 Gastrointestinal Health and Intestinal Barrier Function
Preclinical Evidence (Animal/In Vitro)
The bulk of the evidence for tributyrin's gut-protective effects comes from animal models. The data demonstrate for the first time that supplementation of mice with tributyrin, either as part of a liquid diet or as an oral gavage, prevented ethanol-induced down-regulation of proteins involved with maintaining the intestinal epithelial barrier and transporting butyrate. In these studies, providing tributyrin orally protects against intestinal barrier losses with preservation of the tight junction protein complex and preserves expression of several genes and proteins involved with water and electrolyte balance, butyrate transport, and inflammation.
In a 2025 mouse study of inflammatory diarrhea, high-dose oral tributyrin, but not oral sodium butyrate, improved SCFA transporter expression, barrier properties, and microbial diversity in the colon. An in vitro simulation study found that cytokine responses to an inflammatory signal (LPS) were impacted by tributyrin supplementation; secretion of the anti-inflammatory cytokine IL-10 was increased in the presence of tributyrin-supplemented proximal and distal colonic fermentations following LPS exposure, while secretion of the pro-inflammatory cytokine TNF-α was decreased in the presence of proximal colon fermentations. Tributyrin also induced an enrichment of Akkermansia muciniphila in the distal colon for two of the three healthy donors tested, and the abundance of Akkermansia muciniphila is inversely correlated with several diseases including inflammatory bowel disease, diabetes, and obesity.
Human/Clinical Evidence
Few studies evaluating tributyrin supplementation in humans are available. A pilot randomized, double-blind, placebo-controlled study (published in 2024) investigated a tributyrin-containing complex (ButyraGen®) in healthy adults. The main findings were: 1) the supplement was well tolerated; 2) fecal acetic and propionic acids were decreased in the combined dose group analysis; 3) gut microbiota composition was unchanged; 4) serum triglyceride concentrations were increased after supplementation with the high dose; 5) hs-CRP, a marker of inflammation, was moderately reduced in both dosage groups; and 6) glucose was moderately reduced in the low dose group. The results regarding microbiota may not be unexpected given that most butyrate exposure from ingestion of tributyrin occurs in the small intestine as a result of hydrolysis by lipases, and limited butyrate likely reaches the proximal colon after oral supplementation.
A proposed mechanism of action involves butyrate generation in the small intestine by the action of pancreatic enzymes on tributyrin, followed by absorption into the portal vein and then activity in the liver. These studies have limitations to consider: while in vitro simulations allow for in-depth study of both the effects of test products on the gut microbiome and the mechanisms behind these effects, findings from these studies do not translate directly to in vivo effects. As such, further studies in humans are needed to confirm these findings.
Evidence characterization: Human clinical evidence for tributyrin's effects on gut health is preliminary and sparse. Animal and in vitro data are consistent and promising, but the translation to human outcomes remains underexplored.
4.2 Alcohol-Associated Liver and Gut-Liver Axis Injury
Preclinical Evidence (Animal Models)
A substantial body of preclinical work, primarily from researchers at the Cleveland Clinic, has characterized tributyrin's protective effects in ethanol-exposure models. Prophylactic tributyrin supplementation mitigated effects of combined chronic-binge ethanol exposure on disruption of intestinal TJ localization and intestinal permeability and liver injury. When provided during animal models of acute and chronic-binge ethanol exposure, tributyrin supplementation not only preserves the intestinal barrier but also is hepatoprotective. Previous studies have reported that tributyrin treatment during alcohol feeding decreased liver Toll-like receptor and tumor necrosis factor α expression and also prevented ethanol-induced disruption of intestinal tight junction proteins and intestinal permeability. Tributyrin supplementation prevented these alcohol-mediated changes and reduced fat accumulation and liver injury.
One study examined the gut-lung axis: tributyrin supplementation during ethanol exposure rescued gut bacterial function (p < 0.05), small intestinal barrier integrity, and immune responses, as well as reducing both Ly6G mRNA (p < 0.05) and lipocalin-2 mRNA (p < 0.01) in the lungs.
Evidence characterization: Evidence for protection of the gut-liver axis during alcohol exposure is derived exclusively from animal (murine) models. No human trials in this application have been published. The data highlight beneficial effects of butyrate and suggest an important role of this gut fermentation byproduct as a potential protective supplement to ethanol exposure, and future studies investigating its role in human models are warranted.
4.3 Oncology (Cancer) — Preclinical and Early Clinical Evidence
In Vitro and Animal Evidence
Tributyrin is a prodrug of butyrate known to induce tumor cells to differentiate. In HT-29 colon cancer cells, tributyrin inhibited tumor cell proliferation in a reversible and dose-dependent manner (0.5–4 mM) with significant morphological changes. The IC50 value was 1 mM after 6 days, compared to an IC50 of 2.2 mM for sodium butyrate at equimolar concentration. These results show that tributyrin is more active than butyrate in suppressing cell growth and concomitantly promoting differentiation of HT-29 colon cancer cells. In prostate cancer models, both sodium butyrate and tributyrin had a considerable treatment effect on microtumors on the chicken egg at already very low concentrations of 0.1 mM. Tributyrin-treated tumors showed the strongest effect with 38% apoptotic nuclei in the prostate cancer cell line PC3.
Human Clinical Evidence
The most significant human clinical data come from a phase I/pharmacologic study conducted at the University of Maryland Greenebaum Cancer Center and published in Cancer Chemotherapy and Pharmacology (2003). Twenty patients with advanced solid tumors for whom no other therapy was available were treated with tributyrin at doses from 150 to 200 mg/kg three times daily. The patients comprised 15 men and 5 women with a median age of 61 years (range 30–74 years); prior therapy regimens included a median of two chemotherapy regimens. There was no dose-limiting toxicity. Dose escalation was halted at the 200 mg/kg three times daily level due to the number of capsules required. A median butyrate concentration of 52 μM was obtained, but there was considerable interpatient variability. No objective tumor responses were seen. There were four patients with prolonged disease stabilization ranging from 3 to 23 months; median progression-free survival was 55 days. Two patients with chemotherapy-refractory non-small-cell lung cancer had survived for more than one year at the time of the report without evidence of progression. The conclusion was that tributyrin is well tolerated and levels associated with in vitro activity are achievable with three times daily dosing.
Evidence characterization: The oncology evidence is limited to preclinical models and a single small, uncontrolled phase I dose-finding study. No phase II or III trials for tributyrin in cancer have been published. The phase I study was not designed to demonstrate efficacy. Preclinical evidence is consistent across multiple cancer cell types, but clinical translation remains unestablished.
4.4 Neurology — Parkinson's Disease and Cognitive Function
Preclinical Evidence
Animal research has explored tributyrin's role in brain health. A study published in PMC (2022) found that the activation of AMPK by tributyrin would account, at least partially, for the effect of this drug on long-term potentiation (LTP) as well as on memory and synaptic plasticity. Tributyrin supplementation has also been reported to increase non-rapid-eye movement sleep in mice.
Human Clinical Evidence
An open-label target engagement study at the University of Michigan, published in Neurotherapeutics (2025), represents the most detailed human clinical investigation of tributyrin in a neurological condition. Tributyrin's safety profile and potential biomechanistic effects were investigated in Parkinson's disease via an open-label target engagement study; fourteen individuals with Parkinson's disease and three normal controls completed a 30-day (±7 days) intervention of dietary tributyrin supplementation (500 mg taken orally three times daily), demonstrating a reassuring safety profile with high rates of adherence. Ten subjects completed [¹¹C]butyrate PET imaging before and after the intervention to assess for treatment-related changes in brain, liver, heart, and gastrointestinal uptake of butyrate, confirming target engagement — that is, organ-specific changes in butyrate availability. The most notable statistically significant changes were observed in the brain, spleen, liver, and myocardium. Exploratory clinical analyses revealed that tributyrin supplementation was associated with improvements in both cognitive and motor features.
With emerging evidence suggesting that gut-brain axis dysfunction plays a role in PD pathophysiology, researchers sought to examine the effect of tributyrin supplementation on sleep, motor symptoms, and inflammatory blood markers in people with PD. Their phase 1b pilot study included seven adults diagnosed with PD (mean age 65.6 years) who underwent baseline motor and cognitive assessments, sleep tracking, and fasted blood labs.
Evidence characterization: The Parkinson's disease findings are from a very small, open-label, uncontrolled study with no comparator arm. The study was explicitly designed for target engagement, not efficacy. Results are preliminary and hypothesis-generating. Controlled trials are needed before any conclusions about efficacy in PD or other neurological conditions can be drawn.
4.5 Metabolic Health
Animal studies have explored tributyrin's potential in metabolic disorders. A PMC-published study in suckling piglets with intrauterine growth retardation found tributyrin supplementation attenuated insulin resistance and abnormal lipid metabolism. A study on Caco-2 cells showed that butyrate causes a noticeable reduction in secreted triglycerides (27%) and phospholipids (25%) and suggested potential regulation of circulating lipoprotein concentrations. In the human pilot study with ButyraGen®, fecal acetic and propionic acids decreased after supplementation, and there were trends in decreased hs-CRP after 200 mg (p = 0.08) and 400 mg (p = 0.07) supplementation and decreased glucose (p = 0.10) after 200 mg supplementation.
Evidence characterization: Metabolic effects in humans are tentative, based on small pilot studies with non-significant trends. Controlled human trials in metabolic disease are lacking.
4.6 Microbiome Modulation
Bedford and Gong reported that butyrate glycerides shift caecal microbiota toward beneficial, butyrate-producing bacteria that enhance host metabolism. Tributyrin also reduced coliform counts and modulated the microbial community, further supporting its role as an effective antibiotic alternative. However, in the human pilot study, no significant shifts in gut microbial composition, including those related to butyrate production, were observed with ButyraGen® supplementation. This discrepancy may be explained by the site of tributyrin hydrolysis; when butyrate is supplemented orally, the majority is absorbed in the small intestine, and relatively little butyrate reaches the colon.
5. Body Systems and Health Areas of Association
- Gastrointestinal Tract: Gut barrier integrity, tight junction protein expression, intestinal permeability, colonocyte energy metabolism, and mucosal immune responses.
- Liver: Impaired gut-liver axis is a potential factor contributing to alcoholic liver disease, and tributyrin has been shown in animal models to be hepatoprotective in the context of ethanol exposure.
- Immune System: While the intestine is the largest immune organ in the body, the effects of ethanol on intestinal immune function have been little studied; this work is aimed at investigating the effects of butyrate supplementation, in the form of the structured triglyceride tributyrin, on intestinal innate immune responses and oxidative stress following chronic-binge ethanol exposure.
- Central Nervous System: The gut-brain axis, brain butyrate metabolism, cognition, motor function (particularly in Parkinson's disease), and sleep architecture.
- Epigenome: Class I HDAC inhibition and consequent effects on gene expression in intestinal, hepatic, and neoplastic cells.
- Metabolic System: Glucose regulation, lipid metabolism, and insulin sensitivity (animal and preliminary human data only).
- Pulmonary System: Preclinical evidence of gut-lung axis interactions in the context of alcohol exposure and tributyrin supplementation.
6. Dosage Forms and Dosages Reported in Studies
The following dosages are drawn directly from published studies and clinical trial documentation and do not represent recommendations:
- Phase I Oncology Trial (Edelman et al., 2003 — University of Maryland): Treated with tributyrin at doses from 150 to 200 mg/kg three times daily. Blood was sampled for pharmacokinetic analysis prior to dosing and at 15 and 30 min and 1, 1.5, 2, 2.5, 3, 3.5 and 4 h thereafter. Dose escalation was halted at the 200 mg/kg three times daily level due to the number of capsules required.
- Parkinson's Disease Open-Label Study (Neurotherapeutics, 2025 — University of Michigan): 500 mg taken orally three times daily (1,500 mg/day total) for 30 days (±7 days).
- Healthy Adult Pilot Study (Smith et al., 2024 — ButyraGen®): ButyraGen® is a promising tributyrin-containing complex that can be taken daily at a safe and tolerable level. The study used doses of 200 mg and 400 mg. ButyraGen® was well-tolerated, with less than 10% (n = 2) reporting gastrointestinal-related discomfort. Fecal acetic (p = 0.03) and propionic (p = 0.03) acids decreased after supplementation compared to baseline.
- Animal Models (Ethanol Studies, Cresci et al.): Tributyrin (0.83 to 10 mM) was supplemented either into the liquid diet or by oral gavage. Chronic-binge models supplemented diets with 5 mM tributyrin.
Previous work demonstrated actions of tributyrin in people with solid tumors at pharmacological doses. This extremely high amount of butyrate or butyrate precursor would not be acceptable for acute or chronic daily supplement use for maintenance of health.
7. Safety Considerations and Notable Interactions
General Tolerability
Compared with butyrate, tributyrin has more favorable pharmacokinetics and is well tolerated. Tributyrin is safe when provided at lower doses, but can be cytotoxic at higher doses (e.g., in vivo, ≥10.3 g/kg; in vitro, >10 mM). Questionnaire-based results indicated ButyraGen® was well tolerated by all individuals, and no adverse effects related to the supplement were observed at doses of 200–400 mg/day.
Adverse Effects Reported in Clinical Trials
In the phase I oncology trial, which used very high pharmacological doses (150–200 mg/kg three times daily), grade 3 toxicities consisted of nausea, vomiting, and myalgia. Grades 1 and 2 toxicities included diarrhea, headache, abdominal cramping, nausea, anemia, constipation, azotemia, lightheadedness, fatigue, rash, alopecia, odor, and dysphagia. Minimal toxicity was observed overall, with only two patients experiencing grade 3 adverse effects. It should be noted, as the literature acknowledges, that these trials were designed for cancer treatment where toxic side effects of treatment are accepted and did not use placebo control groups; therefore, it cannot be concluded that these were true adverse effects of the treatment.
Triglyceride Elevation
Secondary effects of butyrate generation and absorption were observed in the ButyraGen® trial, including significant increases in triglycerides, which may be attributed to participants taking an active dose containing tributyrin on the same day blood samples were collected, as tributyrin is a triglyceride-based supplement. This is an important consideration for individuals with pre-existing hypertriglyceridemia or metabolic syndrome.
Pharmacokinetic Limitations
While the half-life of tributyrin is longer than that of butyric acid and sodium butyrate, the absorption kinetics of tributyrin require very large oral doses to reach therapeutic plasma levels (Cmax), which makes effective dosing difficult due to poor taste and smell. Once butyrate enters circulation, its half-life is measured in minutes.
Sodium Butyrate Comparator Note
Sodium butyrate, a comparator form, is a crystalline solid; however, sodium butyrate is over 20% sodium, making its use as a butyrate supplement contraindicated in persons with high blood pressure or those following a low-sodium diet. Tributyrin does not carry this sodium load, which is one of its noted formulation advantages.
Dosage Context for Adverse Event Reporting
In the study by Conley et al., an adverse event was reported at a dose of 50 mg/kg, which may not be related to the intervention according to the investigators. Regardless, a 50 mg/kg dose corresponds to 3,500 mg of tributyrin for a 70 kg individual, which is 17.5 times the highest dose in the ButyraGen® supplementation trial. This dose-context distinction is important when interpreting adverse event data across different studies.
Overall Safety Characterization
Previous tributyrin supplementation trials in humans by Conley et al. and Edelman et al. also concluded tributyrin is generally tolerable, though both studies were conducted at considerably higher dosage levels than dietary supplement doses. At the supplemental dose levels examined in the 2024 healthy adult pilot study (200–400 mg/day), no significant adverse effects were reported.
References
Go back